PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
January 17 2023 - 6:50AM
Business Wire
PhaseOne is uniquely formulated with NovaBay
Pharmaceuticals’ unique and proprietary hypochlorous acid
PhaseOne Health announces the expansion of its commercial
program for PhaseOne Skin and Wound Care Cleanser through
collaborative partnerships with innovative wound dressing
manufacturers and key wound and burn care specialists in the United
States. PhaseOne is formulated with NovaBay Pharmaceuticals’ (NYSE
American: NBY) patented, stable hypochlorous acid.
“We expect wound care to be a larger part of our business in
2023 and we are excited to partner with PhaseOne Health to grow our
sales in the coming year,” said Justin Hall, CEO of NovaBay
Pharmaceuticals.
Kris Perkins, Managing Director of PhaseOne Health, further
explained, “We are building on triple-digit percentage growth over
the last few years by aligning with key opinion leaders and
advisors to expand our commercial programs in 2023. Combining our
past commercial success with recent results in new clinical
applications positions us well to pursue synergistic business and
protocol development with other companies and providers to address
large market opportunities not only in wound care but in other
surgical applications as well.”
PhaseOne is pure hypochlorous acid (HOCI), a part of the body’s
natural immune system. HOCl is widely known as safe and effective
for managing biofilm, bacteria, and fungi to promote the healing
process. Naturally produced by the body’s white blood cells, HOCl
was first synthesized by French scientist Antoine Jerome Balard in
1834 however its use in clinical applications has expanded greatly
within the past 10 years. While PhaseOne is primarily used for pre-
and post-plastic surgery procedures, this coming year will bring an
increased focus in the wound care market.
PhaseOne differentiates itself in the wound care market by
utilizing NovaBay’s unique formulation of HOCI. Through its
proprietary manufacturing process and amber glass bottle, NovaBay
ensures the safest, purest, most powerful HOCl wound cleanser on
the market. Its effectiveness is independently documented in the
study Comparative Antimicrobial Activity of Commercial Wound Care
Solutions on Bacterial and Fungal Biofilms (Harriott, PhD et al)
published in the peer-reviewed journal Annals of Plastic
Surgery.
“The Comparative Antimicrobial Activity study is unique and
compelling because of the large number of bacterial species
evaluated. Even more significant is the large number of bacterial
and fungal strains evaluated within each of these groups. This
study documented the efficacy of HOCI in general for penetrating
biofilm and killing numerous gram-negative and gram-positive
bacteria as well as fungi. It also showed that when hypochlorous
acid is stored in UV-resistant glass, such as Phase One, compared
to plastic, there is a trend for faster action in penetrating
biofilm and killing associated organisms. When dealing either with
a surgical pocket or a wound, purity and speed of action are more
likely to benefit the clinical situation,” said Jack Fisher, MD,
Chief Medical Officer of PhaseOne Health. “Due to PhaseOne Health’s
recent successes in the wound care market, we will be looking to
expand our efforts.”
Mr. Perkins added, “This year we are excited to focus on
partnering with organizations committed to providing more
efficient, cost-effective healing solutions and therapies for wound
and burn patients. We will also continue supporting independent
studies that further explore utilization of PhaseOne in other
specializations like women’s health. We are looking forward to
seeing PhaseOne Health continue to impact the wound care market and
help to heal those in need.”
About PhaseOne Health and HOCl:
PhaseOne Health hypochlorous acid safely penetrates
biofilm. Biofilm represents a significant barrier to wound
healing. PhaseOne (HOCl) solution is effective at penetrating
biofilm and mitigating its complications. PhaseOne is a broad
spectrum non-toxic and non-irritating solution and does not lead to
anti-microbial resistance.
Based in Nashville, TN, PhaseOne Health licenses, markets and
distributes PhaseOne, a registered trademark of NovaBay
Pharmaceuticals, Inc.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 OTC
dermatologist-developed skincare products through the DERMAdoctor
website, well-known traditional and digital beauty retailers, and
international distributors. NovaBay also manufactures and sells
effective, yet gentle and non-irritating wound care products. The
PhaseOne® brand is distributed through commercial partners in the
U.S. for professional use only, and the NeutroPhase® brand is
distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230117005165/en/
PhaseOne Health: info@phaseonehealth.com
NovaBay Pharmaceuticals: info@novabay.com
Investors: jcain@lhai.com Jody Cain LHA Investor Relations
310-691-7100
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2023 to Apr 2024